Cytokinetics (CYTK) FY2017 results: revenue $13 million, down 87.4% on the year
Cytokinetics Inc. (CYTK) reported revenue of $13 million for fiscal 2017, the year ended 31 December 2017, down 87.4% on the year before. Net income was -$128 million, and diluted earnings per share $-2.59. The figures are the company's own, from the 10-K it filed with the SEC on 5 March 2018.
Revenue
$13 million
-87.4% on the year
FY2010FY2017
Operating margin
-848.3%
17.6% a year earlier
FY2010FY2017
Net income
-$128 million
FY2010FY2017
Diluted EPS
-$2.59
FY2010FY2017
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Revenue
13.4
106
28.7
-87.4%
Research and development
90.3
59.9
46.4
+50.8%
Operating income
-113
18.7
-37.4
Operating margin
-848.3%
17.6%
-130.5%
Interest expense
3.0
2.7
0.3
+11.8%
Pre-tax income
-128
16.5
-37.5
Income tax
0.0
0.0
0.0
Effective tax rate
n/a
0.0%
n/a
Net income
-128
16.5
-37.5
Net margin
-955.9%
15.5%
-130.9%
Diluted EPS
-$2.59
$0.39
-$0.97
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Operating cash flow
-102
37.0
4.9
Capital expenditure
2.9
1.6
0.6
+80.3%
Free cash flow
-105
35.4
4.3
Free cash flow margin
-782.7%
33.3%
15.1%
Cash from investing
-65.8
n/a
n/a
Cash from financing
226
n/a
n/a
Depreciation and amortisation
1.9
0.7
0.6
+159.1%
Share-based compensation
9.0
7.1
4.6
+26.3%
Diluted shares, weighted
49m
43m
39m
+16.1%
Shares outstanding at period end
54m
41m
40m
+32.8%
Balance sheet
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Shareholders' equity
110
94.4
68.6
+16.4%
Debt
31.8
29.9
14.6
+6.3%
Other liabilities
153
45.9
32.0
+233.7%
Total liabilities and equity
295
170
115
+73.3%
Fixed assets
3.6
3.6
1.8
-1.9%
Investments
160
97.0
46.5
+65.1%
Cash and equivalents
125
66.9
65.1
+87.2%
Receivables
1.1
0.0
n/a
+4,533.3%
Other assets
4.7
2.6
1.9
+84.4%
Total assets
295
170
115
+73.3%
10-K for the year ended 31 December 2017, filed 5 March 2018: the filing.